ISRCTN37568749
9 evidence topics · 3 sources
Objective
Cessation efficacy objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Study population
Treatment
Treatment and follow-up
| Characteristic | Quoted value |
|---|---|
| Treatment duration | “25 days” |
| Behavioral intervention | “minimal amount of counseling” |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Sustained 12-month abstinence
| Cytisine | Placebo |
|---|---|
| “8.4% (31 participants)” | “2.4% (9 participants)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Gastrointestinal adverse events
| Characteristic | Quoted value |
|---|---|
| Absolute excess with cytisine, percentage points | “5.7” |
Study limitations
Summary
This was a single-center trial with minimal counseling and a 25-day cytisine regimen. Its results do not directly test the 6-week or 12-week, 3 mg three-times-daily regimen evaluated in ORCA-2.